Skip to main content
Fig. 2 | Genome Medicine

Fig. 2

From: The neuroimmune axis of Alzheimer’s disease

Fig. 2

Investigational drugs and proposed targets for the treatment of Alzheimer’s disease and related dementia (ADRD), focusing on those that have been approved or progressed to Phase 2/3 or beyond in U.S. clinical trials. This up-to-date dataset was obtained from alzforum.org, a resource provided by FBRI LLC

Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us